Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Mailing List
ATTEND
Show Overview
Who Attends
Official Event App
Stay Updated
FAQ
COMMUNITIES
Drug Development
Clinical/TMF
BD&L
PR & Communications
PROGRAM
2026 Speakers
2026 Full Agenda
Drug Development Sessions
Clinical/TMF Sessions
BD&L Sessions
PR & Communications Sessions
Speaker Resources
OUTSOURCING AWARDS
Awards Overview
2026 Winners
2026 Judges
Join Our Mailing List
2026 CALL FOR SPEAKERS
PARTNERS
2027 Partner Opportunities
Become a Partner
2026 Partners
STAY CONNECTED
ATTEND
Show Overview
Who Attends
Official Event App
Stay Updated
FAQ
COMMUNITIES
Drug Development
Clinical/TMF
BD&L
PR & Communications
PROGRAM
2026 Speakers
2026 Full Agenda
Drug Development Sessions
Clinical/TMF Sessions
BD&L Sessions
PR & Communications Sessions
Speaker Resources
OUTSOURCING AWARDS
Awards Overview
2026 Winners
2026 Judges
Join Our Mailing List
2026 CALL FOR SPEAKERS
PARTNERS
2027 Partner Opportunities
Become a Partner
2026 Partners
STAY CONNECTED
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
Mailing List
After the Warning Letter: What Clinical QA Actually Owns When AI Enters the Trial
Wed, May 13
|
01:15 PM - 01:40 PM
Picasso 3
Add to Calendar
Calendar only.
Registration required to attend.
Apple
Google Calendar
Outlook
Session details:
More details to follow soon
Speakers:
Kevin Anderson
Biotech AI Advisor
Tags:
Clinical Operations
Track:
Clinical/TMF